Macaldowie, A., Wang, Y. A., Chambers, G. M., & Sullivan, E. A. (2014). Assisted Reproductive Technology in Australia and New Zealand 2012. AIHW National Perinatal Epidemiology and Statistics Unit.
Macaldowie A, Wang YA, Chambers GM, Sullivan EA. Assisted Reproductive Technology in Australia and New Zealand 2012. AIHW National Perinatal Epidemiology and Statistics Unit; 2014.
Macaldowie, A., et al. Assisted Reproductive Technology in Australia and New Zealand 2012. AIHW National Perinatal Epidemiology and Statistics Unit, 2014.
For EndNote, Zotero or Mendeley:
License
Open-access status not yet checked.
RRM Academy Synopsis
Many Women Stop ART Treatment After One Failed Cycle
The registry followed 16,565 women who began treatment in Australia and New Zealand in 2009. It tracked their cycles through 2012. About 2 out of 10 had a baby in their first cycle. About a quarter of women stopped treatment each time a cycle failed, even though later cycles still worked for some.
Key Findings
In a cohort of 16,565 women starting ART in 2009, 21.1% achieved a live delivery in cycle one, falling to 8.0% by cycle ten.
Between 23.4% and 28.7% of women who did not have a baby in a given cycle did not return for further treatment, at every cycle from the first to the tenth.
Across Australia and New Zealand, 70,082 ART cycles in 2012 led to a clinical pregnancy 23.9% of the time and a live delivery 17.9% of the time.
Women under 30 had a 26.0% live delivery rate per fresh or thaw cycle; women over 44 had 0.9% for fresh cycles and 4.6% for thaw cycles.
The multiple delivery rate fell from 8.4% in 2008 to 6.5% in 2012, as single embryo transfer rose from 67.8% to 76.3% of embryo transfer cycles.
Interpretation
The source is a national clinical registry of routine practice. It describes a real cohort of 16,565 women who began ART treatment in Australia and New Zealand in 2009. Researchers tracked them through 2012, or until a live birth. The report counts outcomes by cycle number. The report does not explain why a woman stopped: reasons such as poor prognosis, a natural pregnancy, or financial and emotional factors were not recorded. The findings describe treatment as it was practiced from 2008 to 2012. All 37 fertility centers supplied the 2012 data. They may not reflect current protocols or other countries' registries.
RRM Context
Registry numbers like these show how ART is used in the real world: many cycles, changing odds, and many women who stop treatment. Restorative reproductive medicine takes a different path. It looks for a fixable cause before any procedure.
Our editorial summary of this paper, not the article's abstract.
Key figures
Treatment activity, 2012
Measure
Value
Source
Total ART treatment cycles performed in Australia and New Zealand, 2012
70,082
Summary
ART treatment cycles performed in Australia, 2012
64,905
Summary
ART treatment cycles performed in New Zealand, 2012
5,177
Summary
Increase in ART treatment cycles in Australia compared with 2011
5.8%
Summary
Decrease in ART treatment cycles in New Zealand compared with 2011
0.2%
Summary
ART treatments using a woman's own oocytes or embryos (autologous), 2012
95.2%
Summary
ART cycles using frozen/thawed embryos, 2012
34.8%
Summary
Women who undertook autologous fresh and/or thaw ART cycles, 2012
36,171
Summary
Average number of autologous fresh and/or thaw ART cycles per woman, 2012
1.8
Summary
Fresh cycles among autologous ART cycles, 2012
42,299 (63.4%)
Treatment overview
Pregnancy and birth outcomes, 2012
Measure
Value
Source
Clinical pregnancy rate per initiated ART cycle, 2012
23.9%
Summary
Live delivery rate per initiated ART cycle, 2012
17.9%
Summary
Live delivery rate per initiated autologous fresh cycle, 2012
16.7%
Summary
Live delivery rate per autologous fresh embryo transfer, 2012
22.8%
Summary
Live delivery rate per initiated autologous thaw cycle, 2012
20.5%
Summary
Live delivery rate per autologous thaw embryo transfer, 2012
22.2%
Summary
Live delivery rate for women under 30, autologous fresh and thaw cycles combined, 2012
26.0%
Summary
Live delivery rate for women over 44, autologous fresh cycles, 2012
0.9%
Summary
Live delivery rate for women over 44, autologous thaw cycles, 2012
4.6%
Summary
Babies born and multiples, 2012
Measure
Value
Source
Babies born following ART treatment, 2012
13,590
Summary
Liveborn babies following ART treatment, 2012
13,312
Summary
Liveborn babies that were full-term singletons of normal birthweight, 2012
76.4%
Summary
Patient age, 2012
Measure
Value
Source
Women undergoing an autologous ART cycle aged 40 or older, 2012
approximately 25.3%
Summary
Average age of women undergoing autologous ART cycles, 2012
35.8
Summary
Cycle-specific live birth, first ART cycle cohort (started 2009)
Measure
Value
Source
Women in cohort followed from first autologous fresh ART cycle, starting 2009
16,565
Cycle-specific success rates
Cycle-specific live delivery rate in first autologous fresh ART cycle, cohort started 2009
21.1%
Cycle-specific success rates
Multiple births, 2008 to 2012
Measure
Value
Source
Multiple delivery rate for ART, Australia and New Zealand combined
8.4% to 6.5%
Summary
Multiple delivery rate for ART in Australia, 2012
6.6%
Summary
Multiple delivery rate for ART in New Zealand, 2012
5.2%
Summary
Embryo transfer practice, 2008 to 2012
Measure
Value
Source
Single embryo transfer (SET) proportion of ART cycles
67.8% to 76.3%
Summary
Treatment procedure trends, 2008 to 2012
Measure
Value
Source
Blastocyst transfer proportion of ART cycles
42.0% to 59.8%
Summary
ICSI use proportion of ART cycles
59.1% to 64.7%
Summary
Our summary of the report's published figures, each citing its table, figure or section. The full report is at the publisher's link.
A global reference to national IVF registries (HFEA, RTAC, ANZARD, Q-IVF, CDC, DIR, JSOG, CARTR Plus, REDLARA, ESHRE EIM, ICMART) and the codes of practice that govern fertility clinics. What each measures, and what they miss.